Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Choosing a first-line antihypertensive

Murray M. Finkelstein
CMAJ November 02, 1999 161 (9) 1101;
Murray M. Finkelstein
PhD, MD CM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In their systematic review of antihypertensive therapies, James M. Wright and colleagues conclude that "low-dose thiazide therapy can be prescribed as the first-line treatment of hypertension with confidence that the risk of death, coronary artery disease and stroke will be reduced. The same cannot be said for high-dose thiazide therapy, β-blockers, calcium-channel blockers or ACE [angiotensin-converting-enzyme] inhibitors."1 Although there may be good reasons for selecting thiazide therapy, such as low cost and low rate of withdrawal for adverse effects, the efficacy data in Table 4 do not support the authors' conclusions that only low-dose thiazide therapy will prevent death and cardiovascular morbidity in patients with hypertension.

Table 4 shows that there was essentially no difference among low-dose thiazide, high-dose thiazide, and calcium-channel blocker therapy with respect to mortality (relative risks 0.89, 0.90 and 0.86 respectively) or total cardiovascular events (relative risks 0.68, 0.72 and 0.71 respectively). For total cardiovascular events, a Mantel-Haenszel analysis2 finds no evidence of heterogeneity between these medications (χ2 = 3.6 on 2 degrees of freedom, p = 0.16). There was lower risk reduction for β-blockers than for the other medications, but there was no significant difference between the β-blockers and low-dose thiazide therapy for mortality (relative risk 1.01 and 0.89 respectively). For the β-blockers, the risk reduction for total cardiovascular events just failed to reach significance at the 5% level (relative risk 0.89, 95% confidence interval 0.78-1.02). There were no trials of ACE inhibitors against placebo, but the one trial comparing ACE inhibitors with calcium-channel blockers (Table 2) suggested that the ACE inhibitor was at least as good as the calcium-channel blockers in reducing mortality and cardiovascular events.

I conclude that the data presented by Wright and colleagues show that low- and high-dose thiazide therapy, calcium-channel blockers and ACE inhibitors are similarly efficacious in reducing mortality and cardiovascular events in patients with hypertension.

References

  1. 1.↵
    Wright JM, Lee C-H, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? CMAJ 1999;161(1):25-32.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1998.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 161, Issue 9
2 Nov 1999
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Choosing a first-line antihypertensive
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Choosing a first-line antihypertensive
Murray M. Finkelstein
CMAJ Nov 1999, 161 (9) 1101;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Choosing a first-line antihypertensive
Murray M. Finkelstein
CMAJ Nov 1999, 161 (9) 1101;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

Collections

  • Topics
    • Cardiology: hypertension
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire